



LUND UNIVERSITY

Genetic Determinants of Long-Term Changes in Blood Lipid Concentrations: 10-Year Follow-Up of the GLACIER Study.

V Varga, Tibor; Sonestedt, Emily; Shungin, Dmitry; Koivula, Robert; Hallmans, Göran; Escher, Stefan A; Barroso, Inês; Nilsson, Peter; Melander, Olle; Orho-Melander, Marju; Renström, Frida; Franks, Paul

Published in:
PLoS Genetics

DOI:
[10.1371/journal.pgen.1004388](https://doi.org/10.1371/journal.pgen.1004388)

2014

[Link to publication](#)

Citation for published version (APA):

V Varga, T., Sonestedt, E., Shungin, D., Koivula, R., Hallmans, G., Escher, S. A., Barroso, I., Nilsson, P., Melander, O., Orho-Melander, M., Renström, F., & Franks, P. (2014). Genetic Determinants of Long-Term Changes in Blood Lipid Concentrations: 10-Year Follow-Up of the GLACIER Study. *PLoS Genetics*, 10(6), Article e1004388. <https://doi.org/10.1371/journal.pgen.1004388>

Total number of authors:
12

General rights

Unless other specific re-use rights are stated the following general rights apply:
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117
221 00 Lund
+46 46-222 00 00



Genetic Determinants of Long-Term Changes in Blood Lipid Concentrations: 10-Year Follow-Up of the GLACIER Study

Tibor V. Varga¹, Emily Sonestedt², Dmitry Shungin^{1,3,4}, Robert W. Koivula¹, Göran Hallmans⁵, Stefan A. Escher¹, Inês Barroso^{6,7,8}, Peter Nilsson⁹, Olle Melander¹⁰, Marju Orho-Melander², Frida Renström^{1,5}, Paul W. Franks^{1,4,11*}

1 Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Lund University, Skåne University Hospital Malmö, Malmö, Sweden, **2** Department of Clinical Sciences, Diabetes and Cardiovascular Disease - Genetic Epidemiology, Skåne University Hospital, Malmö, Sweden, **3** Department of Odontology, Umeå University, Umeå, Sweden, **4** Department of Public Health & Clinical Medicine, Umeå University, Umeå, Sweden, **5** Department of Biobank Research, Umeå University, Umeå, Sweden, **6** NIHR Cambridge Biomedical Research Centre, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, United Kingdom, **7** University of Cambridge, Metabolic Research Laboratories Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, United Kingdom, **8** Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom, **9** Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden, **10** Department of Clinical Sciences, Hypertension and Cardiovascular Diseases, Skåne University Hospital, Malmö, Sweden, **11** Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, United States of America

Abstract

Recent genome-wide meta-analyses identified 157 loci associated with cross-sectional lipid traits. Here we tested whether these loci associate (singly and in trait-specific genetic risk scores [GRS]) with longitudinal changes in total cholesterol (TC) and triglyceride (TG) levels in a population-based prospective cohort from Northern Sweden (the GLACIER Study). We sought replication in a southern Swedish cohort (the MDC Study; N = 2,943). GLACIER Study participants (N = 6,064) were genotyped with the MetaboChip array. Up to 3,495 participants had 10-yr follow-up data available in the GLACIER Study. The TC- and TG-specific GRSs were strongly associated with change in lipid levels ($\beta = 0.02$ mmol/l per effect allele per decade follow-up, $P = 2.0 \times 10^{-11}$ for TC; $\beta = 0.02$ mmol/l per effect allele per decade follow-up, $P = 5.0 \times 10^{-5}$ for TG). In individual SNP analysis, one TC locus, *apolipoprotein E* (APOE) rs4420638 ($\beta = 0.12$ mmol/l per effect allele per decade follow-up, $P = 2.0 \times 10^{-5}$), and two TG loci, *tribbles pseudokinase 1* (TRIB1) rs2954029 ($\beta = 0.09$ mmol/l per effect allele per decade follow-up, $P = 5.1 \times 10^{-4}$) and *apolipoprotein A-I* (APOA1) rs6589564 ($\beta = 0.31$ mmol/l per effect allele per decade follow-up, $P = 1.4 \times 10^{-8}$), remained significantly associated with longitudinal changes for the respective traits after correction for multiple testing. An additional 12 loci were nominally associated with TC or TG changes. In replication analyses, the APOE rs4420638, TRIB1 rs2954029, and APOA1 rs6589564 associations were confirmed ($P \leq 0.001$). In summary, trait-specific GRSs are robustly associated with 10-yr changes in lipid levels and three individual SNPs were strongly associated with 10-yr changes in lipid levels.

Citation: Varga TV, Sonestedt E, Shungin D, Koivula RW, Hallmans G, et al. (2014) Genetic Determinants of Long-Term Changes in Blood Lipid Concentrations: 10-Year Follow-Up of the GLACIER Study. *PLoS Genet* 10(6): e1004388. doi:10.1371/journal.pgen.1004388

Editor: Mark I. McCarthy, University of Oxford, United Kingdom

Received: January 3, 2014; **Accepted:** April 1, 2014; **Published:** June 12, 2014

Copyright: © 2014 Varga et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This particular project was supported by project grants from the Swedish Heart-Lung Foundation, The Heart Foundation of Northern Sweden, and the Swedish Research Council including BBMRI.se; additional funding for the GLACIER Study has come from the Swedish Diabetes Association, Pålsson's Foundation, Novo Nordisk, Umeå Medical Research Foundation, and the Wellcome Trust. MDC: This study was supported by grants from the Swedish Research Council (MOM, OM, PN), Swedish Heart-Lung Foundation (MOM), Novo Nordisk Foundation (MOM), Pålsson Foundation (MOM), Swedish Diabetes Foundation (MOM), Lundströms Foundation (PN), and by an equipment grant from Knut and Alice Wallenberg Foundation, and Linneus Foundation for the Lund University Diabetes Center. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: Paul.Franks@med.lu.se

Introduction

The implementation of genome-wide association studies (GWAS) into large, well-characterized cohort collections has spurred the discovery of hundreds of genetic variants for complex cardiometabolic disorders [1]. Of those variants, many have been for blood lipids, with a total of 164 common single nucleotide polymorphisms (SNPs) identified to date at a genome-wide significance level ($P \leq 5 \times 10^{-8}$) [2,3]. These findings come from large-scale, cross-sectional meta-analyses with sufficient power to detect variants with very small effect-sizes for the corresponding

traits (OR ≈ 1.01). Although demonstrating cross-sectional genetic associations is important (e.g., for elucidating biological pathways), from a clinical perspective, the discovery of genetic variants that predict a worsening of lipid levels over time might be more relevant [4]; to our knowledge, no large prospective cohort study focused on the full spectrum of established lipid loci has yet been performed.

The purpose of this study was to examine the predictive ability of 157 established lipid loci (as defined by 164 SNPs), singly and together (genetic risk score (GRS)), on changes in lipid concentrations over a decade of follow-up. Replication analyses in another Swedish cohort were also performed.

Author Summary

Although large cross-sectional studies have proven highly successful in identifying gene variants related to lipid levels and other cardiometabolic traits, very few examples of well-designed longitudinal studies exist where associations between genotypes and long-term changes in lipids have been assessed. Here we undertook analyses in the GLACIER Study to determine whether the 157 previously identified lipid-associated genes variants associate with changes in blood lipid levels over 10-yr follow-up. We identified a variant in *APOE* that is robustly associated with total cholesterol change and two variants in *TRIB1* and *APOA1* respectively that are robustly associated with triglyceride change. We replicated these findings in a second Swedish cohort (the MDC Study). The identified genes had previously been associated with cardiovascular traits such as myocardial infarction or coronary heart disease; hence, these novel lipid associations provide additional insight into the pathogenesis of atherosclerotic heart and large vessel disease. By incorporating all 157 established variants into gene scores, we also observed strong associations with 10-yr lipid changes, illustrating the polygenic nature of blood lipid deterioration.

Results

GLACIER Study participant characteristics are shown in Table 1 (baseline only) and Table 2 (longitudinal subset). The cross-sectional MetaboChip genotype data from the GLACIER Study were combined with many other cohorts in one of the prior lipid meta-analyses [3]. Malmö Diet and Cancer (MDC) Study participant characteristics are shown in Table 3.

The results for cross-sectional analyses in the GLACIER Study are presented in Text S1. The established SNPs explained 8.8%, 4.9%, 9.1% and 4.8% variance for TC, TG, LDL-C and HDL-C, respectively. The weighted GRS (wGRS) (allele counts multiplied by previously published effect sizes for each SNP) explained 7.0%, 3.9%, 6.9% and 2.6% of the variance in TC, TG, LDL-C and HDL-C, respectively.

Longitudinal analyses

A statistically significant overall decrease in plasma TC concentrations between the baseline and follow-up visits (mean change = -0.18 ± 1.12 mmol/l; $P < 0.0001$), but no change in the TG levels (mean change = 0.02 ± 1 mmol/l; $P = 0.32$), was observed.

In individual SNP analysis, Benjamini-Hochberg false discovery rate (FDR) corrected statistically significant associations were observed for the rs6589564 and Δ TG ($\beta = 0.31$ mmol/l per allele per decade follow-up, 95% CI: 0.21, 0.41, SE = 0.05, $P_{FDR} = 6.6 \times 10^{-7}$), rs2954029 and Δ TG ($\beta = 0.09$ mmol/l per allele per decade follow-up, 95% CI: 0.03, 0.15, SE = 0.03, $P_{FDR} = 0.009$) and rs4420638 and Δ TC ($\beta = 0.12$ mmol/l per allele per decade follow-up, 95% CI: 0.06, 0.18, SE = 0.03, $P_{FDR} = 0.002$). One additional SNP (rs2131925) showed nominally significant evidence of association with Δ TC ($\beta = 0.07$ mmol/l per allele per decade follow-up, 95% CI: 0.03, 0.11, SE = 0.02, $P = 0.002$, $P_{FDR} = 0.083$). Seven and five additional SNPs were also nominally statistically associated with Δ TC and Δ TG, respectively ($P < 0.05$), but did not survive multiple-test corrections. Nominally significant SNP associations are shown in Table 4 and all longitudinal SNP associations are reported in Table S1.

The GRSs were strongly associated with their corresponding trait ($\beta = 0.02$ mmol/l per allele per decade follow-up, 95% CI:

0.01, 0.03, SE = 0.003, $P = 2.0 \times 10^{-11}$ for Δ TC; $\beta = 0.02$ mmol/l per allele per decade follow-up, 95% CI: 0.01, 0.03, SE = 0.005, $P = 0.0005$ for Δ TG). Using the wGRS increased the strength and magnitude of the associations for both traits ($\beta = 0.02$ mmol/l per allele per decade follow-up, 95% CI: 0.01, 0.03, SE = 0.003, $P = 9.8 \times 10^{-18}$ for Δ TC; $\beta = 0.03$ mmol/l per allele per decade follow-up, 95% CI: 0.02, 0.04, SE = 0.005, $P = 6.5 \times 10^{-11}$ for Δ TG) (Figure 1A–B). The difference between the highest and lowest quartiles of the wGRS was 0.037 mmol/l for Δ TC, and 0.032 mmol/l for Δ TG.

The variance in lipid changes explained by the wGRS, the baseline lipid measure, sex, age and age² were 33% and 25% for TC and TG, respectively. However, the wGRSs alone explained a small fraction of these proportions ($< 0.05\%$ for both traits).

To compare the predictive accuracy of traditional risk factors, genetic factors and combined models in relation to hyperlipidemia at follow-up, receiver operating characteristics area under the curve (ROC AUC) analyses were performed. The specificities of the predictive models were above 95%, while the sensitivities of the models were below 20%. The ROC AUC curves are shown in Figure 2A–B, and the pairwise differences and classification statistics in the models for high TC and high TG are shown in Table 5. The lowest ROC AUC values were obtained for the basic models including only age, age², sex and BMI (62% and 65% for high TC and high TG, respectively) and the highest for the combined genetic-lifestyle models (66% and 67% for high TC and high TG, respectively). The difference between these two models was statistically significant for high TC ($P = 0.011$) and approached nominal statistical significance for high TG ($P = 0.052$).

Replication and meta-analysis

As described above, 15 variants (16 associations, as rs2131925 associated with both Δ TC and Δ TG) were nominally associated with change in TG or TC over 10-years follow-up in the GLACIER Study. Results of replication analyses in MDC are presented in Table 6. Associations for five SNPs (rs2131925, rs2954029, rs4420638, rs442177, rs6511720) for Δ TC and six SNPs (rs11057408, rs2072183, rs2131925, rs2954029, rs442177, rs6589564) for Δ TG were nominally statistically ($P < 0.05$) significant and directionally consistent with GLACIER results in MDC. Furthermore, four SNPs (rs2954029, rs4420638, rs442177, rs6511720) also associated with Δ LDL-C. None of the SNPs associated with Δ HDL-C in MDC. All three previously associated variants (rs2954029 and rs6589564 in relation to Δ TG and rs4420638 for Δ TC) in GLACIER replicated in MDC.

Meta-analysis results for the 15 longitudinally associated variants are shown in Table S2. Three Δ TC associated variants and six Δ TG associated variants had statistically significant pooled effects ($P < 0.05$).

Discussion

This study extends work reported in two recent large-scale cross-sectional GWAS meta-analyses for lipid loci [2,3] by examining these variants in the setting of a prospective cohort study (10-yr follow-up). The trait-specific GRSs were strongly associated with their corresponding lipid traits in both cross-sectional and longitudinal models. Three previously associated variants yielded statistically significant main effects in the longitudinal analyses, namely the *APOA1* rs6589564 and Δ TG ($P_{FDR} = 7.3 \times 10^{-7}$), the *TRIB1* rs2954029 and Δ TG ($P_{FDR} = 0.013$) and the *APOE* rs4420638 and Δ TC ($P_{FDR} = 0.002$). We used rs6589564 as the best available proxy in our panel for the *APOA1* rs964184 variant (distance = 24.8 kb; $r^2 = 0.688$; $D' = 1$) [5].

Table 1. Baseline characteristics of the GLACIER Study participants (N = 5,862).

	Data available, N	Mean (SD)	Median (IQR)	%
Sex (male/female)	5,862	-	-	61/39
Age (years)	5,862	48.4 (8.7)	50 (40, 60)	-
BMI (kg/m ²)	5,862	25.7 (4.0)	25.2 (22.9, 27.7)	-
TG (mmol/l)*	4,335	-	1.32 (1.0, 1.7)	-
TC (mmol/l)	5,839	6.0 (1.3)	5.9 (5.1, 6.8)	-
HDL-C (mmol/l)	3,096	1.4 (0.4)	1.4 (1.2, 1.6)	-
LDL-C (mmol/l)	3,085	4.3 (1.2)	4.3 (3.5, 5.0)	-
High TG (no/yes)	4,335	-	-	73/27
High TC (no/yes)	5,839	-	-	28/72
Lipid lowering medication (no/yes)	5,862	-	-	99/1

BMI - body mass index; HDL-C - high density lipoprotein cholesterol; IQR - interquartile range; LDL-C - low density lipoprotein cholesterol; SD - standard deviation; TC - total cholesterol; TG - triglyceride.

*Only median is reported for TG, as the trait's distribution is not Gaussian.

doi:10.1371/journal.pgen.1004388.t001

Tentative evidence for association was observed for *angiopoietin-like 3* (*ANGPTL3*) rs2131925 and Δ TC ($P = 0.002$, $P_{FDR} = 0.083$), which given the high prior for association, likely reflects an additional locus that influences changes in lipid levels. These statistically significant associations in GLACIER were successfully replicated in MDC ($P = 4.0 \times 10^{-5}$ for *APOA1* rs6589564 and Δ TG; $P = 5.0 \times 10^{-5}$ for *TRIB1* rs2954029 and Δ TG; $P = 0.01$ for *APOE* rs4420638 and Δ TC; $P = 0.03$ for *ANGPTL3* rs2131925 and Δ TC) and 9 of the 16 nominally significant associations in GLACIER remained significant after meta-analyzing the two cohorts. In ROC analyses, the combined genetic-lifestyle model had higher predictive ability than other models for both traits, but after Bonferroni correction of ROC AUC comparative P values, this difference was not statistically significant.

Two large, recent cross-sectional meta-analyses identified a total of 164 new variants associated with blood lipid levels [2,3]. Whilst these studies highlight numerous, previously unknown biologic pathways underlying dyslipidemia, they have focused exclusively on cross-sectional data, which may not be informative of the genetic mechanisms underlying the deterioration of blood lipid profiles. Prospective data is clinically more relevant, as knowledge of loci that predict change in lipids over time may provide information for clinical translation and risk prediction [4]; however, the extent to which clinical translation could be realized depends on achieving a high level of predictive accuracy using genetic risk algorithms, which at present is not the case for common cardiometabolic diseases [6]. A small number of prospective genetic association studies for lipid loci have been reported [7–10], but these studies have focused on only a handful of the 157 established lipid-loci. In the present study, we show that the ability of these established lipid loci to predict incident dyslipidemia is low in these Swedish populations; adding the wGRS to the risk prediction model incorporating the conventional risk factors for hyperlipidemia (comparing Model 3 and Model 4 (shown in Table 5)) increased the AUC values by 4% and 2% for high TC and high TG, respectively. This is comparable to the 3% AUC difference for incident hypercholesterolemia reported by Lu et al., although they used an unweighted GRS of only 12 established TC variants [10].

Teslovich et al. reported ~12% variance explained by the 95 loci discovered in their meta-analysis for TC, TG, LDL-C and HDL-C [2]. The 62 lipid loci recently discovered by Willer et al.

explain an additional ~2% of the variance per lipid trait [3]. In Lu et al.'s report, 12 candidate SNPs explained 6.9% of the variance in TC, while Sabatti et al. attributed 4.8%, 6%, and 6% of the total variance in TG, LDL-C and HDL-C to 4–11 GWAS identified SNPs [10,11]. In cross-sectional analyses in the GLACIER Study the variances explained by the established SNPs for TC, TG, LDL-C and HDL-C were 8.8%, 4.9%, 9.1% and 4.8%, respectively.

Aulchenko et al. used GRSs comprising 7–11 lipid loci; the variances explained by these SNPs were 3.9%, 3.0%, 3.4% and 4.8% for TC, TG, LDL-C and HDL-C, respectively [12]. Lutsey et al. evaluated the explained variance by trait specific GRSs, in which they incorporated the 95 loci identified by Teslovich et al.; the explained variance for TC, TG, LDL-C and HDL-C were 6.8%, 6.0%, 6.0% and 1.6%, respectively [7]. In the GLACIER Study, the corresponding wGRSs accounted for 7.0%, 3.9%, 6.9% and 2.6% of the trait variances, respectively.

The *TRIB1* locus, which harbors one of the variants (rs2954029) strongly associated with change in TG in our study, encodes a protein with a regulatory effect on mitogen-activated protein kinases (MAPKs) [13]. Studies in mice suggest that *TRIB1* plays a role in the transcription of lipogenic genes in hepatocytes and thereby affects overall apolipoprotein B (ApoB) particle accumulation, alters particle composition and regulates very large density lipoprotein (VLDL), LDL and TG levels [14]. In humans, *TRIB1* variation has been associated with blood lipid levels [2,3,15,16] and increased risk of coronary artery disease [15,17], ischemic heart disease [18] and myocardial infarction [18]. An *in vitro* study suggested that the protein product of *TRIB1* is in control of vascular smooth muscle cell proliferation and consequently may drive the development of atherosclerosis [19].

We detected a statistically significant association between rs4420638 and TC change. This variant maps to the *APOE-APOC1-APOC2* cluster on chromosome 19. *APOE* translates to ApoE, which is the main apolipoprotein of the chylomicron, and thus crucial for breaking down TG-rich lipoproteins and essential in maintaining normal plasma cholesterol and TG levels. *APOE* variants have been associated with blood lipid levels [2,3,20], familial dyslipoproteinemia [21], polygenic dyslipidemia [22], elevated plasma C-reactive protein levels [23,24], coronary heart disease [20,23], and myocardial infarction [15].

We used rs6589564 as a proxy for the *APOA1* rs964184 variant (chromosome 11). Both variants localize to the *APOA1/C3/A4/*

Table 2. Longitudinal characteristics of the GLACIER Study participants (N=3,495 for TC; N=2,211 for TG).

		Baseline		Follow-up	
		Mean (SD)	Median (IQR)	Mean (SD)	Median (IQR)
TG subset	Sex (male/female, %)	62/38			
	Age (years)	45.9 (6.4)	50 (40, 50)	55.8 (6.4)	60 (50, 60)
	TG (mmol/l)*	-	1.3 (1.0, 1.7)	-	1.3 (1.0, 1.8)
TC subset	Sex (male/female, %)	61/39			
	Age (years)	45.3 (6.7)	50 (40, 50)	55.2 (6.7)	60 (50, 60)
	TC (mmol/l)	5.7 (1.2)	5.6 (4.9, 6.4)	5.5 (1.1)	5.5 (4.8, 6.2)

BMI - body mass index; IQR - interquartile range; SD - standard deviation; TC - total cholesterol; TG - triglyceride.

*Only median is reported for TG, as the trait's distribution is not Gaussian.

doi:10.1371/journal.pgen.1004388.t002

A5/BUD13 cluster. *APOA1* encodes the major apolipoprotein of plasma HDL particles and plays a central role in lipid metabolism. The rs964184 variant in *APOA1* has been associated with blood lipid levels [2,3,22], polygenic dyslipidemia [22], metabolic syndrome [25], coronary heart disease [26], and myocardial infarction [27].

An important strength of this study is the inclusion of replication data. The findings of this study would be enhanced by further investigation of lipoprotein subclasses and the analysis of the effects of lipid lowering interventions in randomized controlled trials.

In conclusion, the trait-specific GRSs were robustly associated with baseline and longitudinal changes in blood lipid concentrations. We detected three novel longitudinal associations in relation to TC and TG changes over a 10-yr follow-up period. As these loci have been previously associated with cardiovascular traits, such as coronary heart disease and myocardial infarction, their associations with lipid changes provide further insight into how these variants contribute to cardiovascular risk.

Materials and Methods

Ethics statement

Ethical approval for the GLACIER Study was obtained from the Regional Ethical Review Board in Umeå, Sweden. The Ethics Committee at Lund University approved the MDC study.

Study participants

The GLACIER Study (N~19,000) is a prospective, population-based cohort study nested within the Västerbotten Health Survey (VHU) in the northern Swedish county of Västerbotten [28]. Baseline examinations were undertaken from 1985 through 2004. GLACIER participants were invited to attend an examination on their 40th, 50th and 60th birthdays. In a subcohort (N=5,010), ten-year follow-up data are also available, of whom 3,495 were genotyped (see below). Anthropometric measures (age, sex, height and weight) were collected, and detailed assessments of lifestyle were obtained using a validated questionnaire [28,29]. All participants provided written informed consent as part of the VHU. The MDC Study constitutes southern Swedish adults participating in a cardiovascular program, with baseline data recorded from 1991 through 1996 [30,31]. All individuals who were alive and still living in Sweden were invited for follow-up between 2007 and 2012. A total of 3,734 individuals attended follow-up investigation and 2,943 individuals with no history of coronary events had available data for replications analyses.

Clinical measures

Clinical measures have been described in detail elsewhere [28,29]. Capillary blood was drawn following an overnight fast. Serum lipid concentrations were measured on fresh capillary plasma with a Reflotron bench-top analyzer (Roche Diagnostics

Table 3. Longitudinal characteristics of the MDC Study participants (N=2,943).

	Baseline		Follow-up	
	Mean (SD) or n (%)	Median (IQR)	Mean (SD) or n (%)	Median (IQR)
Sex (male)	1,148 (39)	-	1,148 (39)	-
Age (years)	56.4 (5.7)	56.1 (9.7)	73.0 (5.6)	73.0 (9.2)
TC (mmol/l)	6.11 (1.06)	6.07 (1.42)	5.59 (0.91)	5.60 (1.20)
TG (mmol/l)*	-	1.10 (0.68)	-	1.00 (0.60)
lnTG (ln mmol/l)	0.125 (0.433)	0.095 (0.60)	0.025 (0.425)	0.000 (0.56)
HDL-C (mmol/l)	1.42 (0.37)	1.38 (0.48)	1.42 (0.44)	1.36 (0.59)
LDL-C (mmol/l)	4.13 (0.96)	4.10 (1.20)	3.67 (0.79)	3.60 (0.91)
BMI (kg/m ²)	25.3 (3.6)	24.9 (4.6)	26.8 (4.4)	26.2 (5.2)

BMI - body mass index; HDL-C - high density lipoprotein cholesterol; IQR - interquartile range; LDL-C - low density lipoprotein cholesterol; SD - standard deviation; TC - total cholesterol; TG - triglyceride.

*Only median is reported for TG, as the trait's distribution is not Gaussian.

doi:10.1371/journal.pgen.1004388.t003

Table 4. Nominally significant SNPs from the longitudinal models in the GLACIER Study (N = 3,495 for ΔTC; N = 2,211 for ΔTG).

Trait	SNP	Locus	EA	EAF	β (95% CI) (mmol/l)	P	P _{FDR}
ΔTC	rs1800562	HFE	G	0.93	0.089 (0.003; 0.176)	0.043	0.36
ΔTC	rs2000999	HPR	A	0.23	0.072 (0.021; 0.123)	0.006	0.15
ΔTC	rs2072183	NPC1L1	C	0.27	0.066 (0.017; 0.114)	0.008	0.15
ΔTC	rs2131925	ANGPTL3	T	0.67	0.072 (0.026; 0.119)	2.2 × 10 ⁻³	0.08
ΔTC	rs4299376	ABCG5/8	G	0.33	0.050 (0.003; 0.098)	0.038	0.36
ΔTC	rs4420638	APOE	G	0.20	0.118 (0.064; 0.173)	2.0 × 10 ⁻⁵	1.5 × 10 ⁻³
ΔTC	rs6511720	LDLR	G	0.92	0.104 (0.026; 0.182)	0.009	0.13
ΔTC	rs6882076	TMD4	C	0.62	0.050 (0.005; 0.095)	0.029	0.36
ΔTC	rs9411489	ABO	T	0.16	0.062 (0.004; 0.120)	0.036	0.38
ΔTG	rs11057408	ZNF664	G	0.63	0.058 (0.005; 0.112)	0.033	0.29
ΔTG	rs1260326	GCKR	T	0.31	0.059 (0.003; 0.116)	0.040	0.24
ΔTG	rs2131925	ANGPTL3	T	0.67	0.064 (0.009; 0.120)	0.023	0.25
ΔTG	rs2954029	TRIB1	A	0.54	0.092 (0.041; 0.143)	4.1 × 10 ⁻⁴	8.8 × 10 ⁻³
ΔTG	rs2972146	IRS1	T	0.60	0.057 (0.004; 0.110)	0.034	0.25
ΔTG	rs442177	KLHL8	T	0.54	0.060 (0.008; 0.112)	0.023	0.33
ΔTG	rs6589564	APOA1	C	0.06	0.308 (0.202; 0.414)	1.5 × 10 ⁻⁸	6.6 × 10 ⁻⁷

95% CI–95% confidence interval; β - beta coefficient; ΔTC - total cholesterol change; ΔTG - triglyceride change; EA - effect allele; EAF - effect allele frequency; FDR - false discovery rate; SE - standard error; SNP - single nucleotide polymorphism
P values are based on linear regression models. SNP associations were tested by fitting the previously associated individual variants (additive model) as the independent variables with lipid trait changes as dependent variables. We adjusted the raw P values for multiple-testing using Benjamini-Hochberg's FDR.
doi:10.1371/journal.pgen.1004388.t004




Figure 1. TC and TG level changes (95% CI) over 10-yr follow-up by wGRS quartiles. The TC wGRS was robustly associated with TC changes over follow-up ($\beta = 0.02$ mmol/l per allele per follow-up, 95% CI = 0.01, 0.03, SE = 0.003, $P = 9.8 \times 10^{-18}$) (A). The TG wGRS was robustly associated with TG changes over follow-up ($\beta = 0.03$ mmol/l per allele per follow-up, 95% CI = 0.02, 0.04, SE = 0.005, $P = 6.5 \times 10^{-11}$) (B). doi:10.1371/journal.pgen.1004388.g001

Scandinavia AB). HDL cholesterol was measured after precipitation of the other lipoproteins with sodium phosphowolframate-magnesium chloride. For the ROC AUC analyses, lipid levels were dichotomized (low/high) according to the American Heart Association criteria [32]. At baseline, 5% of the individuals reported not having fasted for at least 8 hours before the blood draw, and information on fasting time was missing in a further 15% of the participants; therefore analyses were adjusted with a variable indicating fasting status, but this did not materially affect the results. In the MDC Study, TC, TG and HDL-C concentrations in the fasting blood samples were measured with a DAX 48 automatic analyzer (Bayer AB, Göteborg, Sweden) using reagents and calibrators from the supplier of the instrument. HDL-C concentrations were determined by the same procedure as used for TC, but after precipitation of LDL-C and very low-density lipoprotein cholesterol (VLDL-C) with dextran-sulphate [33]. The same laboratory methods were applied for analyzing lipid levels




Figure 2. ROC AUC for high TC (A) and high TG (B) at follow-up. In ROC analyses we excluded individuals with hyperlipidemia at baseline and compared the predictive accuracy of four models (age, sex and BMI (Model 1), Model 1 + trait specific wGRS (Model 2), Model 1

+ traditional risk factors for hyperlipidemia (Model 3) and M1 + trait specific GRS + traditional risk factors for hyperlipidemia (Model 4)) in relation to hyperlipidemia at follow-up.
doi:10.1371/journal.pgen.1004388.g002

at both visits. Direct anthropometry was measured by nurses. LDL-C concentrations were calculated with the Friedewald formula for both studies [34].

Lipid medications

One percent of participants reported using lipid-lowering medications, which we controlled for in analyses using a constant, as described by Tobin *et al* [35]. There was no information available on the specific type of the lipid lowering agent used by the participants, but at the time of the examinations the most common class of lipid lowering drugs in northern Sweden was statins, used by ~96% of lipid lowering medication users [36]. Therefore, to correct lipid levels we used the statin constants proposed by Wu *et al* [37]: HDL-C: -0.059 mmol/l; LDL-C: +1.279 mmol/l, TC: +1.336 mmol/l, TG: +0.207 mmol/l. The MDC Study participants who reported using lipid-lowering-medication at baseline (3%) were excluded from analyses because the type of medication used could not be determined. 28.3% (n = 834) of the MDC Study participants reported using lipid lowering medication at follow-up; of these, 28% used LDL lowering agents (Crestor, Lipitor, Pravachol, Zocord or Ezetrol) and 0.3% used fibrates (Lopid). Their lipid measures were corrected by adding the appropriate constants proposed by Wu *et al* [37].

Genotyping

DNA was extracted from peripheral white blood cells and genomic DNA samples were diluted to 4 ng/μl as previously described [38,39]. Samples were genotyped with the MetaboChip (Illumina iSelect) array [40]. The 102 associated SNPs from Teslovich *et al* [2] and the 62 SNPs from Willer *et al* [3] were extracted from the MetaboChip. We used proxy SNPs for 18 variants. Proxies for two SNPs (the TG-associated rs2929282 and the HDL-C associated-rs1047891 variants) were unavailable. Detailed information about the index and proxy SNPs are shown in Table S3. The average genotyping success rate was 99.9%. None of the SNPs deviated significantly from Hardy-Weinberg expectations at a study-wise corrected level ($P < 0.0001$). Therefore, we conducted our analyses with a total of 162 SNPs (HDL-C = 73 SNPs; LDL-C = 58 SNPs; TC = 75 SNPs; and TG = 43 SNPs). For the replication effort in MDC, the SNPs analyzed were genotyped using Illumina OmniExpress Exome. SNP and proxy information are reported in Table S4.

Genetic risk score

The effects of multiple genetic risk loci on blood lipid traits were studied by constructing two different types of GRS for each study participant. The first assumed an equal magnitude of effect for each risk allele and was generated for each participant by summing the number of risk alleles at each of the associated SNP loci for the respective traits. Thus, because these are all biallelic loci, the GRSs had a minimum possible value of 0 and a maximum possible value of 146, 116, 150 and 86 for HDL-C, LDL-C, TC and TG, respectively. To construct the second GRS, we used published effect sizes for each SNP (from the joint meta-analysis by Willer *et al* [3]) to weight the contribution of each risk allele. The weighted alleles were subsequently summed into a single weighted GRS (wGRS) as previously described [39,41]. Missing genotypes were imputed by mean imputation as

Table 5. Pairwise differences between ROC AUC curves and classification statistics in relation to hyperlipidemia in GLACIER (N = 1,257 for TC; N = 1,660 for TG).

	ROC AUC value (%)		Model 1	Model 2	Model 3	Model 4	Sensitivity	Specificity	PPV	NPV	Correctly classified
high TC subset	Model 1	62	-	-	-	-	0.91%	99.63%	57.14%	65.04%	65.00%
	Model 2	65	0.01	-	-	-	17.23%	93.26%	58.02%	67.58%	66.59%
	Model 3	62	0.93	0.02	-	-	2.32%	98.73%	50.00%	64.86%	64.61%
	Model 4	66	0.01	0.48	0.01	-	19.72%	91.61%	56.29%	67.57%	66.17%
high TG subset	Model 1	65	-	-	-	-	3.21%	99.39%	57.89%	79.77%	79.52%
	Model 2	67	0.11	-	-	-	4.66%	99.09%	57.14%	79.96%	79.58%
	Model 3	65	0.27	0.45	-	-	2.47%	99.21%	44.44%	79.86%	79.46%
	Model 4	67	0.05	0.30	0.12	-	4.32%	99.13%	56.00%	80.15%	79.77%

NPV - negative predictive value; PPV - positive predictive value; ROC AUC - receiver operating characteristics area under the curve; TC - total cholesterol; TG - triglyceride.

P values are calculated by a chi squared test comparing two ROC AUC curves.

Model 1 = age+age²+sex+BMI; Model 2 = Model 1+ trait specific GRS; Model 3 = Model 1+ traditional risk factors (cholesterol intake, trans fat intake, saturated fat intake, carbohydrate intake, alcohol intake, physical activity); Model 4 = Model 1+ trait specific GRS + traditional risk factors.

doi:10.1371/journal.pgen.1004388.t005

Table 6. Replication of lipid associations in MDC (N = 2,943).

SNP	Proxy SNP	EA	EAF	ΔTC		ΔTG		$\Delta LDL-C$		$\Delta HDL-C$	
				β (95% CI) (mmol/l)	P	β (95% CI) (mmol/l)	P	β (95% CI) (mmol/l)	P	β (95% CI) (mmol/l)	P
rs1800562	rs1408272	T	0.95	-0.03 (-0.11; 0.05)	0.50	-0.01 (-0.05; 0.03)	0.48	-0.004 (-0.08; 0.07)	0.91	-0.02 (-0.06; 0.02)	0.25
rs2000999	-	A	0.22	0.02 (-0.02; 0.06)	0.49	0.007 (-0.01; 0.03)	0.54	0.02 (-0.02; 0.06)	0.34	-0.002 (-0.02; 0.02)	0.79
rs2072183	-	C	0.25	0.03 (-0.01; 0.07)	0.27	0.02 (0.00; 0.04)	0.04	0.03 (-0.01; 0.07)	0.12	-0.01 (-0.03; 0.01)	0.13
rs2131925	-	T	0.67	0.04 (0.00; 0.08)	0.05	0.02 (0.00; 0.04)	0.02	0.02 (-0.02; 0.04)	0.20	0.01 (-0.01; 0.03)	0.57
rs4299376	-	G	0.30	-0.01 (-0.03; 0.01)	0.50	-0.01 (-0.03; 0.01)	0.28	-0.02 (-0.06; 0.02)	0.36	0.001 (-0.02; 0.02)	0.99
rs4420638	-	G	0.20	0.07 (0.03; 0.11)	3×10^{-3}	-0.004 (-0.02; 0.02)	0.75	0.08 (0.04; 0.12)	4×10^{-4}	0.01 (-0.01; 0.03)	0.62
rs6511720	-	G	0.90	0.07 (0.01; 0.13)	0.04	0.004 (-0.04; 0.04)	0.81	0.08 (0.02; 0.14)	7×10^{-3}	-0.01 (-0.03; 0.01)	0.42
rs6882076	-	C	0.63	-0.002 (-0.04; 0.04)	0.90	-0.01 (-0.03; 0.01)	0.27	-0.01 (-0.05; 0.03)	0.67	0.01 (-0.01; 0.03)	0.18
rs9411489	rs579459	T	0.77	0.04 (-0.01; 0.08)	0.11	0.004 (-0.02; 0.02)	0.73	0.03 (-0.01; 0.07)	0.21	0.01 (-0.01; 0.03)	0.20
rs11057408	rs4765127	G	0.66	0.001 (-0.04; 0.04)	0.95	0.02 (0.00; 0.04)	0.04	0.01 (-0.03; 0.05)	0.68	-0.01 (-0.03; 0.01)	0.17
rs1260326	-	T	0.36	0.001 (-0.04; 0.04)	0.95	0.02 (-0.00; 0.04)	0.08	0.01 (-0.03; 0.05)	0.64	-0.01 (-0.03; 0.01)	0.18
rs2954029	-	A	0.52	0.04 (0.00; 0.08)	0.05	0.04 (0.02; 0.06)	1×10^{-4}	0.04 (0.00; 0.08)	0.03	-0.01 (-0.03; 0.01)	0.55
rs2972146	-	T	0.63	-0.01 (-0.05; 0.03)	0.47	0.01 (-0.01; 0.03)	0.53	-0.004 (-0.04; 0.04)	0.83	-0.01 (-0.03; 0.01)	0.32
rs442177	-	T	0.57	0.04 (0.00; 0.08)	0.04	0.03 (0.01; 0.05)	1×10^{-3}	0.03 (-0.01; 0.07)	0.05	-0.003 (-0.02; 0.02)	0.73
rs6589564	rs9326246	C	0.06	0.03 (-0.05; 0.11)	0.41	0.07 (0.03; 0.11)	2×10^{-4}	0.03 (-0.05; 0.11)	0.34	-0.02 (-0.06; 0.02)	0.29

95% CI-95% confidence interval; β - beta coefficient; $\Delta HDL-C$ - high density lipoprotein cholesterol change; $\Delta LDL-C$ - low density lipoprotein cholesterol change; ΔTC - total cholesterol change; ΔTG - triglyceride change; EA - effect allele; EAF - effect allele frequency; SE - standard error; SNP - single nucleotide polymorphism

P values for lipid changes are based on linear regression models, marginal effects were tested by fitting the previously statistically nominally significant associated single variants (additive model) as the independent variables with lipid trait changes as dependent variables.

doi:10.1371/journal.pgen.1004388.t006

previously described [42]. To illustrate results in figures we used quartiles of the GRSs.

Statistical methods

Statistical analyses were undertaken using SAS (version 9.3, SAS Institute Inc., NC, USA), STATA (version 12.1, StataCorp LP, TX, USA), *R* (version 2.15.3, The *R* Foundation for Statistical Computing) and PLINK (version 1.07) [43–46]. Main effects were estimated with generalized linear models (GLMs) by fitting genotypes (additive model) or the unweighted/weighted GRSs as the independent variable with the corresponding lipid traits as the dependent variable. We used natural logarithmic transformed TG values for cross-sectional individual SNP analyses and adjusted for age, age², sex, fasting time and population substructure (first four principal components) in all our models. In longitudinal analyses, we included the follow-up lipid measure as the dependent variable and adjusted for the respective trait's baseline value.

$$\text{follow-up lipid} = \alpha + \beta_{\text{SNP/GRS}} + \beta_{\text{baseline lipid}} + \beta_{\text{cov}} + \dots + \beta_{\text{cov}} + \varepsilon$$

For the sake of simplicity, when reporting the estimates for the model above, we refer to ΔTC or ΔTG throughout the manuscript. The Benjamini-Hochberg FDR was used to correct for multiple testing [47]; given the prior knowledge of the SNPs in the analyses, we decided to use a less stringent approach than the Bonferroni or the Holm correction. ROC AUCs were computed and compared using STATA. In these analyses we excluded individuals with hyperlipidemia at baseline and compared the predictive accuracy of four models (age, age², sex and BMI (M1), M1+ trait specific wGRS (M2), M1+ traditional risk factors (age, sex, BMI, smoking status, alcohol intake) [10] for hyperlipidemia (M3) and M1+ trait specific wGRS + traditional risk factors for hyperlipidemia (M4)) in relation to hyperlipidemia at follow-up. Random effects meta-analysis was performed using the *metan* module in STATA [48]. Statistical analyses for MDC were done using SPSS (version 20, IBM Corporation). Linear regression was used to obtain effect sizes (β) and 95% confidence intervals (95% CI) by fitting genotypes (additive model) as the independent variables and follow-up lipid measures (TC, lnTG, HDL-C or

LDL-C) as dependent variables. Baseline lipid levels, sex, age and age² were used as covariates. For meta-analysis, regression estimates with average annual lipid level changes as outcome measures were used.

Supporting Information

Table S1 Longitudinal associations of previously associated SNPs in the GLACIER Study. (XLSX)

Table S2 Meta-analysis of effect estimates from GLACIER and MDC. (XLSX)

Table S3 Original and proxy SNPs used in cross-sectional and longitudinal models in the GLACIER Study. (XLSX)

Table S4 Original and proxy SNPs used in longitudinal models in MDC. (XLSX)

Text S1 Cross-sectional analyses results in GLACIER. (PDF)

Acknowledgments

GLACIER: We thank the participants, health professionals and data managers involved in the Västerbottens Intervention Project. We are also grateful to the staff of the Northern Sweden Biobank for preparing materials and to K Enqvist and T Johansson (Västerbottens County Council, Umeå, Sweden) for DNA preparation. MDC: We thank the participants, health professionals, data managers and biobank staff involved in the Malmö Diet and Cancer Study. We also thank M Svensson and W Tas for the excellent technical assistance.

Author Contributions

Conceived and designed the experiments: TVV PWF. Analyzed the data: TVV RWK ES SAE. Contributed reagents/materials/analysis tools: GH DS IB PN OM MOM FR PWF. Wrote the paper: TVV PWF.

References

1. Visscher PM, Brown MA, McCarthy MI, Yang J (2012) Five years of GWAS discovery. *Am J Hum Genet* 90: 7–24.
2. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, et al. (2010) Biological, clinical and population relevance of 95 loci for blood lipids. *Nature* 466: 707–713.
3. Global Lipids Genetics Consortium, Willer CJ, Schmidt EM, Sengupta S, Peloso GM, et al. (2013) Discovery and refinement of loci associated with lipid levels. *Nat Genet* 45: 1274–1283.
4. Middelberg RP, Martin NG, Whitfield JB (2006) Longitudinal genetic analysis of plasma lipids. *Twin Res Hum Genet* 9: 550–557.
5. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'Donnell CJ, et al. (2008) SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. *Bioinformatics* 24: 2938–2939.
6. Jostins L, Barrett JC (2011) Genetic risk prediction in complex disease. *Hum Mol Genet* 20: R182–188.
7. Luitsey PL, Rasmussen-Torvik IJ, Pankow JS, Alonso A, Smolenski DJ, et al. (2012) Relation of lipid gene scores to longitudinal trends in lipid levels and incidence of abnormal lipid levels among individuals of European ancestry: the Atherosclerosis Risk in Communities (ARIC) study. *Circ Cardiovasc Genet* 5: 73–80.
8. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, et al. (2012) Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. *Lancet* 380: 572–580.
9. Costanza MC, Beer-Borst S, James RW, Gaspoz JM, Morabia A (2012) Consistency between cross-sectional and longitudinal SNP: blood lipid associations. *Eur J Epidemiol* 27: 131–138.
10. Lu Y, Feskens EJ, Boer JM, Imholz S, Verschuren WM, et al. (2010) Exploring genetic determinants of plasma total cholesterol levels and their predictive value in a longitudinal study. *Atherosclerosis* 213: 200–205.
11. Sabatti C, Service SK, Hartikainen AL, Pouta A, Ripatti S, et al. (2009) Genome-wide association analysis of metabolic traits in a birth cohort from a founder population. *Nat Genet* 41: 35–46.
12. Aulchenko YS, Ripatti S, Lindqvist I, Boomsma D, Heid IM, et al. (2009) Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. *Nat Genet* 41: 47–55.
13. Kiss-Toth E, Bagstaff SM, Sung HY, Jozsa V, Dempsey C, et al. (2004) Human tribbles, a protein family controlling mitogen-activated protein kinase cascades. *J Biol Chem* 279: 42703–42708.
14. Burkhardt R, Toh SA, Lagor WR, Birkeland A, Levin M, et al. (2010) Trib1 is a lipid- and myocardial infarction-associated gene that regulates hepatic lipogenesis and VLDL production in mice. *J Clin Invest* 120: 4410–4414.
15. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, et al. (2008) Newly identified loci that influence lipid concentrations and risk of coronary artery disease. *Nat Genet* 40: 161–169.
16. Kathiresan S, Melander O, Guiducci C, Surri A, Burt NP, et al. (2008) Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. *Nat Genet* 40: 189–197.
17. Waterworth DM, Ricketts SL, Song K, Chen L, Zhao JH, et al. (2010) Genetic variants influencing circulating lipid levels and risk of coronary artery disease. *Arterioscler Thromb Vasc Biol* 30: 2264–2276.
18. Varbo A, Benn M, Tybjaerg-Hansen A, Grande P, Nordestgaard BG (2011) TRIB1 and GSKR polymorphisms, lipid levels, and risk of ischemic heart disease in the general population. *Arterioscler Thromb Vasc Biol* 31: 451–457.
19. Sung HY, Guan H, Czibula A, King AR, Eder K, et al. (2007) Human tribbles-1 controls proliferation and chemotaxis of smooth muscle cells via MAPK signaling pathways. *J Biol Chem* 282: 18379–18387.

20. Drenos F, Talmud PJ, Casas JP, Smeeth L, Palmen J, et al. (2009) Integrated associations of genotypes with multiple blood biomarkers linked to coronary heart disease risk. *Hum Mol Genet* 18: 2305–2316.
21. Smelt AH, de Beer F (2004) Apolipoprotein E and familial dysbetalipoproteinemia: clinical, biochemical, and genetic aspects. *Semin Vasc Med* 4: 249–257.
22. Kathiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, et al. (2009) Common variants at 30 loci contribute to polygenic dyslipidemia. *Nat Genet* 41: 56–65.
23. Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, et al. (2009) Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. *JAMA* 302: 37–48.
24. Golledge J, Biros E, Cooper M, Warrington N, Palmer LJ, et al. (2010) Apolipoprotein E genotype is associated with serum C-reactive protein but not abdominal aortic aneurysm. *Atherosclerosis* 209: 487–491.
25. Kristiansson K, Perola M, Tikkanen E, Kettunen J, Surakka I, et al. (2012) Genome-wide screen for metabolic syndrome susceptibility Loci reveals strong lipid gene contribution but no evidence for common genetic basis for clustering of metabolic syndrome traits. *Circ Cardiovasc Genet* 5: 242–249.
26. Xu L, Zhou J, Huang S, Huang Y, Le Y, et al. (2013) An association study between genetic polymorphisms related to lipoprotein-associated phospholipase A(2) and coronary heart disease. *Exp Ther Med* 5: 742–750.
27. Tragante V, Doevendans PA, Nathoe HM, van der Graaf Y, Spiering W, et al. (2013) The impact of susceptibility loci for coronary artery disease on other vascular domains and recurrence risk. *Eur Heart J* 34: 2896–2904.
28. Hallmans G, Agren A, Johansson G, Johansson A, Stegmayr B, et al. (2003) Cardiovascular disease and diabetes in the Northern Sweden Health and Disease Study Cohort - evaluation of risk factors and their interactions. *Scand J Public Health Suppl* 61: 18–24.
29. Norberg M, Wall S, Boman K, Weinehall L (2010) The Vasterbotten Intervention Programme: background, design and implications. *Glob Health Action* 3.
30. Hedblad B, Nilsson P, Janzon L, Berglund G (2000) Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmo, Sweden. *Diabet Med* 17: 299–307.
31. Manjer J, Carlsson S, Elmstahl S, Gullberg B, Janzon L, et al. (2001) The Malmo Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants. *Eur J Cancer Prev* 10: 489–499.
32. American Heart Association (AHA) - What Your Cholesterol Levels Mean. Available: http://www.heart.org/HEARTORG/Conditions/Cholesterol/AboutCholesterol/What-Your-Cholesterol-Levels-Mean_UCM_305562_Article.jsp. Accessed 05 May 2013.
33. Rosvall M, Ostergren PO, Hedblad B, Isacson SO, Janzon L, et al. (2000) Occupational status, educational level, and the prevalence of carotid atherosclerosis in a general population sample of middle-aged Swedish men and women: results from the Malmo Diet and Cancer Study. *Am J Epidemiol* 152: 334–346.
34. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 18: 499–502.
35. Tobin MD, Sheehan NA, Scurrah KJ, Burton PR (2005) Adjusting for treatment effects in studies of quantitative traits: antihypertensive therapy and systolic blood pressure. *Stat Med* 24: 2911–2935.
36. Eliasson M, Janlert U, Jansson JH, Stegmayr B (2006) Time trends in population cholesterol levels 1986–2004: influence of lipid-lowering drugs, obesity, smoking and educational level. The northern Sweden MONICA study. *J Intern Med* 260: 551–559.
37. Wu J, Province MA, Coon H, Hunt SC, Eckfeldt JH, et al. (2007) An investigation of the effects of lipid-lowering medications: genome-wide linkage analysis of lipids in the HyperGEN study. *BMC Genet* 8: 60.
38. Franks PW, Rolandsson O, Debenham SL, Fawcett KA, Payne F, et al. (2008) Replication of the association between variants in WFS1 and risk of type 2 diabetes in European populations. *Diabetologia* 51: 458–463.
39. Renstrom F, Payne F, Nordstrom A, Brito EC, Rolandsson O, et al. (2009) Replication and extension of genome-wide association study results for obesity in 4923 adults from northern Sweden. *Hum Mol Genet* 18: 1489–1496.
40. Voight BF, Kang HM, Ding J, Palmer CD, Sidore C, et al. (2012) The metabochip, a custom genotyping array for genetic studies of metabolic, cardiovascular, and anthropometric traits. *PLoS Genet* 8: e1002793.
41. Cornelis MC, Qi L, Zhang C, Krafi P, Manson J, et al. (2009) Joint effects of common genetic variants on the risk for type 2 diabetes in U.S. men and women of European ancestry. *Ann Intern Med* 150: 541–550.
42. Fontaine-Bisson B, Renstrom F, Rolandsson O, Magic, Payne F, et al. (2010) Evaluating the discriminative power of multi-trait genetic risk scores for type 2 diabetes in a northern Swedish population. *Diabetologia* 53: 2155–2162.
43. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 81: 559–575.
44. SAS Institute (2011) The SAS system for Windows, version 9.2. SAS Institute, Cary, NC, USA.
45. StataCorp (2011) Stata Statistical Software, version 12.1. College Station, TX: StataCorp LP, USA.
46. R Development Core Team (2008) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
47. Miller RG (1981) Simultaneous statistical inference. 2nd ed.: Springer Verlag. pp. 6–8.
48. Harris RJ, Deeks JJ, Altman DG, Bradburn MJ, Harbord RM, et al. (2008) metan: fixed- and random-effects meta-analysis. *The Stata Journal* 8: pp. 3–28.